Until now, it was unclear as to whether drugs that clear amyloid, which accumulate in the brain during aging and accompany diseases such as Alzheimer’s, have any influence over cognitive decline.
Previous studies have aimed to find this out, but results have been inconclusive due to study designs, hard-to-interpret data, and other issues that muddy the waters. March 10-14th saw the 15th International Conference on Alzheimer’s and Parkinson’s Diseases being held (virtually of course), where Dr. Mark Mintun of Eli Lilly presented data that, at least somewhat, affirmatively answers the question [1].
Comments are closed.